CuATSM Compared With Placebo for Treatment of ALS/MND
Status:
Unknown status
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and
efficacy of CuATSM in patients with ALS/MND. Patients will be randomized 1:1 to CuATSM or
placebo for 6 x 28-day cycles (24 weeks) of treatment.